IL280177B2 - Use of riluzole prodrugs for the treatment of Alzheimer's disease - Google Patents
Use of riluzole prodrugs for the treatment of Alzheimer's diseaseInfo
- Publication number
- IL280177B2 IL280177B2 IL280177A IL28017721A IL280177B2 IL 280177 B2 IL280177 B2 IL 280177B2 IL 280177 A IL280177 A IL 280177A IL 28017721 A IL28017721 A IL 28017721A IL 280177 B2 IL280177 B2 IL 280177B2
- Authority
- IL
- Israel
- Prior art keywords
- disease
- pharmaceutical composition
- riluzole
- study
- alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701814P | 2018-07-22 | 2018-07-22 | |
| PCT/US2019/042718 WO2020023324A1 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL280177A IL280177A (en) | 2021-03-01 |
| IL280177B1 IL280177B1 (en) | 2024-09-01 |
| IL280177B2 true IL280177B2 (en) | 2025-01-01 |
Family
ID=69181140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280177A IL280177B2 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs for the treatment of Alzheimer's disease |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12161633B2 (https=) |
| EP (1) | EP3823616A4 (https=) |
| JP (2) | JP2021530543A (https=) |
| KR (1) | KR20210034621A (https=) |
| CN (1) | CN112469408A (https=) |
| AU (1) | AU2019310013B2 (https=) |
| BR (1) | BR112021000768A2 (https=) |
| CA (1) | CA3107215A1 (https=) |
| EA (1) | EA202190308A1 (https=) |
| IL (1) | IL280177B2 (https=) |
| MX (2) | MX2021000515A (https=) |
| NZ (1) | NZ772009A (https=) |
| PH (1) | PH12021550043A1 (https=) |
| SG (1) | SG11202100385YA (https=) |
| WO (1) | WO2020023324A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230027189A (ko) * | 2020-06-24 | 2023-02-27 | 바이오하벤 테라퓨틱스 리미티드 | 강박 장애를 치료하기 위한 조성물 및 방법 |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
| WO2022178425A1 (en) * | 2021-02-22 | 2022-08-25 | Yale University | Targeted bifunctional degraders |
| CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064775A1 (en) * | 2010-03-02 | 2013-03-14 | Universite D'auvergne Clermont I | Use of riluzole for treating or preventing the adverse effects of antineoplastic agents |
| US20180037557A1 (en) * | 2015-03-03 | 2018-02-08 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs riluzole and their method of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214663B2 (en) * | 2000-06-14 | 2007-05-08 | Medarex, Inc. | Tripeptide prodrug compounds |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| EP3079692A4 (en) | 2013-12-09 | 2017-10-18 | Thomas Jefferson University | Novel methods of treating a neurodegenerative disease in a mammal in need thereof |
| WO2016085998A1 (en) * | 2014-11-26 | 2016-06-02 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| WO2017201502A1 (en) * | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| WO2018031707A1 (en) * | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| AU2019223014B2 (en) * | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
-
2019
- 2019-07-20 WO PCT/US2019/042718 patent/WO2020023324A1/en not_active Ceased
- 2019-07-20 CA CA3107215A patent/CA3107215A1/en active Pending
- 2019-07-20 JP JP2021503571A patent/JP2021530543A/ja active Pending
- 2019-07-20 US US17/261,057 patent/US12161633B2/en active Active
- 2019-07-20 EA EA202190308A patent/EA202190308A1/ru unknown
- 2019-07-20 KR KR1020217004639A patent/KR20210034621A/ko not_active Ceased
- 2019-07-20 IL IL280177A patent/IL280177B2/en unknown
- 2019-07-20 EP EP19841953.3A patent/EP3823616A4/en active Pending
- 2019-07-20 NZ NZ772009A patent/NZ772009A/en unknown
- 2019-07-20 AU AU2019310013A patent/AU2019310013B2/en active Active
- 2019-07-20 BR BR112021000768-7A patent/BR112021000768A2/pt unknown
- 2019-07-20 CN CN201980048687.7A patent/CN112469408A/zh active Pending
- 2019-07-20 SG SG11202100385YA patent/SG11202100385YA/en unknown
- 2019-07-20 MX MX2021000515A patent/MX2021000515A/es unknown
-
2021
- 2021-01-07 PH PH12021550043A patent/PH12021550043A1/en unknown
- 2021-01-14 MX MX2024010655A patent/MX2024010655A/es unknown
-
2025
- 2025-02-21 JP JP2025026643A patent/JP2025093952A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064775A1 (en) * | 2010-03-02 | 2013-03-14 | Universite D'auvergne Clermont I | Use of riluzole for treating or preventing the adverse effects of antineoplastic agents |
| US20180037557A1 (en) * | 2015-03-03 | 2018-02-08 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs riluzole and their method of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112469408A (zh) | 2021-03-09 |
| EP3823616A1 (en) | 2021-05-26 |
| US20210290599A1 (en) | 2021-09-23 |
| SG11202100385YA (en) | 2021-02-25 |
| EA202190308A1 (ru) | 2021-05-19 |
| BR112021000768A2 (pt) | 2021-05-11 |
| NZ772009A (en) | 2026-02-27 |
| WO2020023324A1 (en) | 2020-01-30 |
| IL280177A (en) | 2021-03-01 |
| EP3823616A4 (en) | 2022-05-04 |
| IL280177B1 (en) | 2024-09-01 |
| MX2021000515A (es) | 2021-06-08 |
| US12161633B2 (en) | 2024-12-10 |
| KR20210034621A (ko) | 2021-03-30 |
| CA3107215A1 (en) | 2020-01-30 |
| PH12021550043A1 (en) | 2021-09-20 |
| JP2021530543A (ja) | 2021-11-11 |
| AU2019310013A1 (en) | 2021-02-11 |
| AU2019310013B2 (en) | 2025-01-02 |
| JP2025093952A (ja) | 2025-06-24 |
| MX2024010655A (es) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12161633B2 (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| Kiernan et al. | Amyotrophic lateral sclerosis | |
| US20200085816A1 (en) | Lsd for the treatment of alzheimer's disease | |
| US11123332B2 (en) | Gaboxadol for reducing risk of suicide and rapid relief of depression | |
| Reid et al. | A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence | |
| CN105832733A (zh) | 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途 | |
| Benzer et al. | Case 40-2013: a 36-year-old man with agitation and paranoia | |
| US20240082340A1 (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| KR20150119089A (ko) | 알츠하이머병 치료 방법에 사용하기 위한 헬리카제-프리마제 억제제 | |
| US12201618B2 (en) | Use of riluzole prodrugs to treat Alzheimer's disease | |
| Zhang et al. | Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice | |
| WO2023250036A1 (en) | Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc) | |
| US20240408086A1 (en) | Use of luvadaxistat for the treatment of cognitive impairment | |
| Omar et al. | Severe hyponatremia as poor prognostic factor in childhood neurologic diseases | |
| EA049330B1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| US20250375459A1 (en) | Methods for ameliorating cognitive impairment using bile acid derivatives | |
| Ramos-Quiroga et al. | Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults | |
| Khatri et al. | New-onset functional dyspepsia after COVID-19 | |
| FENG et al. | Clinical analysis of 30 cases with Stevens-Johnson syndrome | |
| Bhattacharyya et al. | P0361-Delta-9-tetrahydrocannabinol modulates parahippocampal and ventral striatal activity during processing of verbal memory | |
| Gracious et al. | Child and Adolescent Program of the 42nd Annual National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, Florida, June 10–13, 2002 | |
| Zoing et al. | Motor neurone disease Caring for the patient in general practice | |
| DelaRaillere et al. | Bibliography Current World Literature Vol 15 No | |
| HK1252154B (zh) | 左乙拉西坦的延时释放药物组合物 |